Diggin′ on U(biquitin): A Novel Method for the Identification of Physiological E3 Ubiquitin Ligase Substrates by Rubel, Carrie E. et al.
Diggin’ on U(biquitin): A Novel Method for the Identification of
Physiological E3 Ubiquitin Ligase Substrates
Carrie E. Rubel*,1,2, Jonathan C. Schisler*,2,3, Eric D. Hamlett4, Robert M. DeKroon5,
Mathias Gautel6, Oscar Alzate5, and Cam Patterson2,3
1Department of Pharmacology, University of North Carolina at Chapel Hill, NC, USA
2McAllister Heart Institute, University of North Carolina at Chapel Hill, NC, USA
3Division of Cardiology, University of North Carolina at Chapel Hill, NC, USA
4Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill,
NC, USA
5Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill, NC,
USA
6Cardiovascular Division, BHF Centre of Research Excellence, King’s College London, UK
Abstract
The ubiquitin-proteasome system (UPS) plays a central role in maintaining protein homeostasis,
emphasized by a myriad of diseases that are associated with altered UPS function such as cancer,
muscle-wasting, and neurodegeneration. Protein ubiquitination plays a central role in both the
promotion of proteasomal degradation as well as cellular signaling through regulation of the
stability of transcription factors and other signaling molecules. Substrate specificity is a critical
regulatory step of ubiquitination and is mediated by ubiquitin ligases. Recent studies implicate
ubiquitin ligases in multiple models of cardiac diseases such as cardiac hypertrophy, atrophy, and
ischemia/reperfusion injury, both in a cardioprotective and maladaptive role. Therefore,
identifying physiological substrates of cardiac ubiquitin ligases provides both mechanistic insights
into heart disease as well as possible therapeutic targets. Current methods identifying substrates
for ubiquitin ligases rely heavily upon non-physiologic in vitro methods, impeding the unbiased
discovery of physiological substrates in relevant model systems. Here we describe a novel method
for identifying ubiquitin ligase substrates utilizing Tandem Ubiquitin Binding Entities (TUBE)
technology, two-dimensional differential in gel electrophoresis (2-D DIGE), and mass
spectrometry, validated by the identification of both known and novel physiological substrates of
the ubiquitin ligase MuRF1 in primary cardiomyocytes. This method can be applied to any
ubiquitin ligase, both in normal and disease model systems, in order to identify relevant
physiological substrates under various biological conditions, opening the door to a clearer
mechanistic understanding of ubiquitin ligase function and broadening their potential as
therapeutic targets.
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Introduction
Protein ubiquitination and the ubiquitin-proteasome system (UPS) play a critical role in the
regulation of protein homeostasis, emphasized by a myriad of diseases associated with
aberrant UPS function. Ubiquitin is added to a substrate protein through a covalent linkage
to a lysine residue on a substrate protein catalyzed by a class of enzymes called ubiquitin
ligases; as an additional layer of regulation, this mechanism is counter-regulated by a class
of enzymes called de-ubiquitination enzymes (DUBs) (1,2). The effect of protein
ubiquitination depends upon which lysine residue within the protein the ubiquitin is attached
to as well as the length and linkage type of the added ubiquitin. The UPS is most commonly
thought of in terms of regulating the turnover of mis-folded and damaged proteins by the
addition of canonical K48 polyubiquitin chains and subsequent proteasomal degradation.
However, non-canonical linkages, for example K63 polyubiquitin chains, or single ubiquitin
molecules (monoubiquitination) can also occur and mediates non-proteolytic mechanisms
such as modulating protein localization, protein-protein interactions, activity or stability (3–
5). The essential nature of protein ubiquitination is well illustrated in the heart where
dysfunction, of both proteolytic and non-proteolytic mechanisms, has been associated with
multiple disorders, including cardiac hypertrophy, heart failure, diabetes and ischemia-
reperfusion injury (5).
Substrate specificity of the ubiquitination reaction occurs at the level of the ubiquitin ligase;
as such, ubiquitin ligases are attractive therapeutic targets for diseases involving aberrant
protein ubiquitination (4,6). Muscle-specific RING finger protein 1 (MuRF1, Trim63) is a
striated muscle-specific ubiquitin ligase involved in protein quality control of the muscle
sarcomere by targeting numerous proteins for polyubiquitin-dependent proteasomal
degradation, including troponin I, muscle actin, β/slow myosin heavy chain and myosin
binding protein-C (7–10). Ubiquitin ligases, including MuRF family proteins, function as
distinct molecular regulators by which the heart controls not only sarcomeric structure, but
also cellular signaling pathways implicated in multiple models of cardiac disease, both in
maladaptive and cardioprotective roles (5,9,11–16). Targeting ubiquitin ligases in the heart
may allow for more precise, single therapy manipulation of a smaller, specific subset of
substrate proteins that contribute to disease-causing mechanisms while avoiding the negative
cardiovascular effects observed with global proteasome inhibition (17,18). Yet the substrates
targeted by MuRF1 and their DUB counterparts remain incompletely understood and more
robust identification methods for identifying ubiquitin ligase substrates is required for
development of successful therapies (19).
Traditional ubiquitin ligase substrate discovery utilizes protein-protein interaction based
methods, such as yeast-two hybrid and co-immunoprecipitation paired with mass
spectrometry. Although refined recently by several modifications to increase efficiency in
substrate identification (9,20,21), interaction-based methods are hindered by the transient,
weak nature of the ubiquitin ligase-substrate interaction. To circumvent the limitations of
interaction-based methods, high-throughput in vitro approaches, such as in vitro
ubiquitination biochemistry coupled with protein microarrays, have proven to be successful
at identifying ubiquitin ligase substrates (22,23). The use of in vitro-based methods is
limited, however, to the content printed on protein arrays, limiting the substrate candidate
pool. Importantly, neither yeast-two hybrids nor in vitro methods for ubiquitin ligase
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substrate identification are performed in physiologically relevant conditions, thereby
limiting and biasing substrate discovery (16,24).
Given the limitations of existing ubiquitin ligase substrate screening methods, our aim was
to develop a methodology to better identify candidate ubiquitin ligase substrates under
physiological conditions. Tandem Ubiquitin Binding Entities (TUBE) technology allows
unbiased ubiquitome isolation through high affinity binding to polyubiquitinated proteins.
TUBE also protects polyubiquitiated proteins from de-ubiquitination and degradation during
processing, allowing for detection of even low abundant species (25). Furthermore, the use
of different TUBE types that have higher affinities for specific polyubiquitin lysine linkages
can be used to enrich for subsets of the ubiquitome, providing another potential level of
specificity to the screen. We used a subtractive approach combining TUBE technology, 2-D
DIGE, and mass spectrometry, to develop a method for ubiquitin ligase substrate
identification that is translatable to physiologically relevant inputs, either from cells or
tissues. We describe and validate this method demonstrated by the identification of both
previously identified as well as novel physiological substrates of the ubiquitin ligase MuRF1
in primary cardiomyocytes.
Methods
Neonatal Rat Ventricular Myocyte Isolation and Culture
Neonatal rat ventricular myocytes (NRVM) were isolated from day old Sprague–Dawley
pups utilizing the Worthington Neonatal Cardiomyocyte Isolation System as previously
described and according to manufacturer’s instructions (26). Briefly, isolated neonatal hearts
were sequentially digested at 4 °C overnight with trypsin and then at 37 °C for 2 h with
collagenase type II. After preplating to minimize nonmyocyte contamination, cells were
plated on tissue culture dishes precoated with laminin (Sigma). NRVM were cultured at 37
°C and 5% CO2 in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) with 10%
horse serum, 5% fetal bovine serum and 100 µM 5-bromo-2'-deoxyuridine (BRDU) to
inhibit non-myocyte growth for the first 24 h post isolation and subsequently in a 4:1 ratio of
DMEM:Minimum Essential Medium with 100 µM BRDU. Freshly isolated NRVM were
cultured for 72 h prior to adenoviral infection.
Adenoviral Constructs
Full-length mouse MuRF1 was cloned into the Myc-pCMV vector. Adenovirus plasmids
Ad-GFP and Ad-MuRF1 (the later expressing GFP and Myc-tagged MuRF1 bicistronically)
were constructed in pADTrack-CMV and used as previously described (9).
Adenoviral Infection and TUBE Enrichment for Ubiquitinated Proteins
Six independent 15 cm plates of cultured NRVM were transduced with Ad-GFP or Ad-
MuRF1 at a multiplicity of infection (MOI) of 10 for 18 h. Lysates were prepared by
scraping, trituration and brief sonication of cells in cell lysis buffer containing 50 mM Tris-
HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 50 µM deubiquitinating
enzyme inhibitor PR619 (LifeSensors) and 1X HALT protease/phosphatase inhibitor
(Pierce) followed by clarification by centrifugation at 15,000 × g. Lysates from all plates
transduced with Ad-GFP or Ad-MuRF1 were pooled and total protein concentration
determined by BCA protein assay (Pierce). Lysate containing 1 mg of total protein was
incubated for 18 h at 4 °C with 60 µl of prewashed Agarose TUBE 2 beads (LifeSensors) or
Control Agarose beads (LifeSensors). Unbound supernatant was removed and frozen at −80
°C. Beads were thoroughly washed in 20 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1%
Tween-20 (TBST) and ubiquitinated proteins eluted in 0.2 M glycine, pH 2.5 and
neutralized with 1 M Tris pH9.0. Elutions were stored at −80 °C prior to 2D-DIGE and
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proteomic analysis. Alternatively, ubiquitinated proteins were eluted by resuspending the
beads in 20 µl SDS reducing sample buffer and boiling for 5 m followed by centrifugation at
13000 × g for 5 m. Beads were discarded and eluted samples analyzed by SDS-PAGE and
immunoblotting for Hspd1 (Abcam, ab59457) or total ubiquitin (Lifesensors, VU-1).
Two-Dimensional Differential In Gel Electrophoresis (2D-DIGE)
To detect differential protein expression, samples were first cleaned by methanol/chloroform
precipitation and dissolved in lysis buffer (8 M urea, 20 mM tris-HCl, pH 8.5, 4% CHAPS).
Aliquots of the MuRF1 TUBE eluate, MuRF1 TUBE supernatant, MuRF1 agarose control
supernatant, GFP TUBE eluate, GFP TUBE supernatant, and GFP agarose control
supernatant were labeled with either Cy3 or Cy5 fluorescent dyes. An internal control (IC)
was prepared by pooling equal amounts of protein (15 µg) from all samples, and then
labeled with 200 pmol of Cy2 for every 15 µg of protein. The labeling reaction was carried
out on ice for 30 min, protected from light. To quench the reaction, 1 µL of 10 mM lysine
was added, and the reaction was then incubated for an additional 10 m on ice in the dark.
After labeling, corresponding samples were combined. An equal volume of 2X sample
buffer (8 M urea, 4% CHAPS, 20 mg/mL DTT, 2% (v/v) IPG buffer 4–7 (GE Healthcare))
was added and the mixture was placed on ice for 15 m. Rehydration buffer (8 M urea, 4%
CHAPS, 2 mg/mL DTT, 1% (v/v) IPG buffer 4–7) was added to a final volume of 250 µL.
For each gel IC, Cy3, and Cy5 labeled samples were mixed before applying to immobilized
pH gradient (IPG) strips (24 cm, pI range 4–7, GE Healthcare). Isoelectric focusing and the
subsequent SDS-PAGE (second dimension) were performed as previously described (27).
Three independent gels were run: the first comparing MuRF1 TUBE eluate to GFP TUBE
eluate, the second comparing MuRF1 TUBE supernatant to MuRF1 agarose control
supernatant and the third comparing GFP TUBE supernatant to GFP agarose control
supernatant. Gels were analyzed using DeCyder 7.0 software (GE Healthcare). A “spot
number” of 4500 was used to generate spot maps using the differential in-gel analysis (DIA)
component. Spot maps were filtered via the built-in algorithm using a Max slope of 1.0, and
manually edited to remove dust particle signals. Expression changes were assessed using the
Volume Ratio between samples within each gel.
Spot selection and MALDI-TOF
Protein spots displaying greater than 1.5 fold expression changes were marked as “picks”
and the list of “picks” from all three gel comparisons were aligned to determine spots that
were identified as “picks” by all three comparisons. Spots that were identified as “picks”
across all multiple gels were selected for further analysis and removed from the 2D gels
using an Ettan Spot Picker (GE Healthcare) and submitted to the Michael Hooker
Proteomics Center (University of North Carolina) for protein identification by
matrixassisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry.
With the aid of a Progest Protein Digestion System (Digilab), proteins were digested with
trypsin, and the resulting peptides were extracted. Peptides were mixed with matrix (α-
Cyano-4-Hydroxycinnamic Acid) and analyzed using a MALDI-TOF/TOF mass
spectrometer (Applied Biosystems 4800 Plus). MS spectra were obtained in reflector
positive ion mode and peaks with signal-to-noise ratio above 10 were selected for MS/MS
analysis (maximum of 45 MS/MS spectra per spot). All spectra were searched using GPS
Explorer, Version 3.6 (AB Sciex) linked to the Mascot (Matrix Science, Inc.) search engine
and compared to the IPI rat database downloaded from European Bioinformatics Institute.
Immunofluorescence
24 h post infection with Ad-GFP or Ad-MuRF1, cells were washed with PBS, fixed, and
permeabilized in phosphate-buffered 2% paraformaldehyde/0.2% Triton X-100 for 30
minutes at 4 °C. Immunofluorescence labeling was carried out with a mouse anti-GFP
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(Sigma, G6795) followed by a FITC-conjugated goat anti-mouse secondary antibody
(Jackson ImmunoResearch Laboratories Inc.) and DAPI (Sigma-Aldrich). Images were
acquired by fluorescence-inverted microscopy.
Western blotting
24 h post infection with Ad-GFP or Ad-MuRF1, cells were washed with PBS and lysates
prepared by scraping, trituration and brief sonication of cells in cell lysis buffer containing
50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 50 µM
deubiquitinating enzyme inhibitor PR619 (LifeSensors), and 1X HALT protease/
phosphatase inhibitor (Pierce) followed by clarification by centrifugation at 15,000 × g.
Proteins were separated by SDS-PAGE, transferred to PVDF and detected by Western blot
analysis with anti-myc (Sigma, C3956), anti-MuRF1 (R&D Systems, AF5366), or anti-
GAPDH (Sigma, G8795).
In Vitro Ubiquitination Reactions
In vitro ubiquitination reactions were performed as previously described (28). In brief, 2 µM
human MuRF1 (LifeSensors), 0.25 µM Ube1 (Boston Biochem), 2.5 µM UbcH5c and 10
mg/ml ubiquitin and 500 ng of recombinant Hspd1 (Enzo Life Sciences) or ATP5b
(Abnova) were incubated in 20 µM HEPES, pH 7.4, 10 µM KCl, 5mM ATP, 5mM MgCl2,
and 1X Energy Regeneration Solution (ERS, Boston Biochem) for 3 h at 30 °C. Samples
were analyzed by SDS/PAGE and immunoblotting for ATP5b (Aviva Systems Biology,
ARP48186) or Hspd1 (Abcam, ab59457).
Animals
The MuRF1 transgenic (MuRF1-Tg) mice used in this study were previously described (29).
All animal protocols were reviewed and approved by the University of North Carolina
Institutional Animal Care Advisory Committee and were in compliance with the rules
governing animal use as published by the National Institutes of Health.
Immunoprecipitation from MuRF1 Transgenic Hearts
Whole heart ventricles were excised from anesthetized male wild-type and MuRF1-Tg mice
and homogenized on ice in T-Per tissue protein extraction reagent (Pierce) containing 1X
HALT protease/phosphatase inhibitor (Pierce), 50uM PR619 (Lifesensors), 50uM MG132
(Millipore) and 10mM N-ethylmaleimide (Sigma) first in a 2 ml glass tissue grinder
homogenizer followed by brief homogenization by handheld tissue homogenizer.
Homogenates were clarified by centrifugation at 10,000 × g. Protein G Dynabeads
(Invitrogen) pre-conjugated to 2 µg of Hspd1 (Abcam, ab59457) or Tpm1 (Abcam,
ab133292) antibody or appropriate IgG control were incubated for 1 h at 4 °C with clarified
homogenates. Beads were washed five times with Tris-Buffered Saline with 0.02%
Tween-20 and subsequently, proteins were eluted in SDS-sample buffer and analyzed by
SDS-PAGE and western blotting.
Results
Outline of the methodology used to screen for ubiquitin ligase substrates
Identification of substrates for ubiquitin ligases have traditionally relied on either artificial
systems, such as yeast two-hybrid screens, or inefficient candidate substrate screens. Our
goal for a more robust and flexible substrate screen included the use of biologically relevant
cell systems combined with a proteomic approach for identification. A key component of
this method is the selection, as well as the lack of selection, of polyubiquitinated proteins
immunoprecipitated by Tandem Ubiquitin Binding Entities (TUBE) conjugated to agarose
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beads. This allows us to compare the relative ratio of proteins that bind to TUBE (eluate) as
well as compare proteins that did not bind (supernatant) across multiple conditions. We have
provided a graphical overview of the method (Fig. 1) and discuss below the major
components of this approach.
1) Protein source—Our method relies on a subtractive approach (i.e. comparing one state
to another); therefore the starting material must include two conditions wherein the
expression or activity of the ubiquitin ligase is manipulated. We classify systems where
ubiquitin ligase activity is either increased or decreased as gain-of-function or loss-of-
function, respectively (see Fig. 1 for examples). The starting material can range from protein
isolated from animal tissues, primary cells, or stable cell culture models in which either the
ubiquitin ligase or a counter-regulatory de-ubiquitination enzyme is manipulated.
2) Ubiquitome isolation—Protein extracts are isolated and quantified from each
condition and an equal amount of protein is subsequently added to either agarose control
beads or beads conjugated with TUBE. We used TUBE that bind equally to K48- and K63-
ubiquitin linkages, however, there are other TUBE varieties that preferentially bind certain
lysine linkages that can be used depending on the type of substrates desired (e.g. canonical
versus non-canonical). From each condition we collect both the eluate from the TUBE,
containing the selected ubiquitome, as well as the unbound supernatants from both the
control agarose and TUBE, which provide an additional measure of the ubiquitome from
each condition.
3) 2D-DIGE and pick selection—In order to reduce the number of false positives, we
established a three spot comparison to identify substrate picks. Within each 2D-DIGE gel,
relative differences between the two conditions are quantified. We established three
independent comparisons that are analyzed in parallel to increase the likelihood of positive
substrate identification. The first comparison of the pick selection contrasts the eluted
ubiquitome from the experimental and control condition. In the case of gain-of-function
studies, a spot pick would be increased in the experimental condition compared to the
control condition (converse for loss-of-function models). The second and third gels allow
comparisons of the TUBE-selected ubiquitomes within the experimental condition (Gel 2) or
control condition (Gel 3). In these later comparisons, enriched ubiquitinated proteins are
identified by comparing the unbound fraction from the control agarose beads (ubiquitin-
enriched) versus the unbound fraction from the TUBE agarose (ubiquitin-depleted).
Naturally occurring ubiquitinated proteins in the control condition are identified in Gel 3
whereas Gel 2 identifies the enriched (or depleted in the case of loss-of-function) pool of
proteins in the experimental conditions.
4) Spot pick identification—All of the spots that meet the pick criteria for each Gel are
tabulated and subsequently used to identify picks that are common to all multiple
comparisons (see Figure 1 for the differences in pick criteria in gain-of-function versus loss-
of-function models). These picks are then subjected to MALDI-TOF for protein
identification and classified as potential ubiquitin ligase substrates.
MuRF1 expression in primary cardiomyocytes
Using traditional substrate identification approaches, our laboratory as well as and other
groups identified substrates for MuRF1, a striated muscle-specific ubiquitin ligase. As a
proof of principle for our method, we screened for MuRF1 substrates in primary rat
cardiomyocytes and hypothesized we would identify both previously established substrates
as well as potential novel substrates. We utilized a transient gain-of-function model in
primary cardiomyocytes as previously described through the use of adenoviral-mediated
Rubel et al. Page 6













expression of either the reporter green fluorescent protein (GFP) alone or in combination
with MuRF1 (mouse) at a multiplicity of infection of 10 MOI per cell (Fig. 2A).
Confirmation of the expression of the MuRF1 transgene was performed via immunoblot
detection of the myc epitope tag (Fig. 2B, top) that corresponded to an approximate 25-fold
increase in MuRF1 transgene expression relative to the endogenous MuRF1 expression in
control cells, measured by densitometry, after 18 h of adenoviral transduction. These data
confirm the successful expression of the MuRF1 transgene in primary cardiomyocytes.
MuRF1 ubiquitome isolation
Prior to 2D-DIGE analyses, we first confirmed that we could successfully isolate the TUBE-
selected ubiquitome. Lysates were prepared, quantified, and incubated for 18 h in the
presence of either control agarose or TUBE beads. Both the unbound (supernatant) and
bound (eluate) fractions were collected and separated via SDS-PAGE. The bound fractions
from the TUBE beads in both the Ad-GFP and Ad-MuRF1 conditions contained highly
enriched levels of ubiquitinated proteins compared to the unbound fraction determined via
immunoblot analysis (Fig. 2C). We also consistently noticed a 30% increase in the total
densitometry of ubiquitin immunoreactivity in cells transduced with Ad-MuRF1 (Fig. 2C,
right) suggesting an overall increase in total protein ubiquitination in the presence of
increased MuRF1 expression. Given the successful selection of ubiquitinated proteins using
the TUBE isolation procedure, we moved forward to the differential gel analysis to attempt
to identify specific proteins that are more readily ubiquitinated in the presence of increased
MuRF1 expression.
2D-DIGE and selection of picks corresponding to increased MuRF1 expression
Using the three gel conditions outlined above (Fig. 1) we used 2D-DIGE to identify
candidate picks from each of the three comparisons. The primary comparison was between
the elution profiles of the GFP versus MuRF1 ubiquitome (Gel 1). As shown in Figure 3,
2D-DIGE resolved differentially fluorescent-labeled pools of proteins in the same gel
separated by both molecular weight (MW, vertical) and isoelectric point (pH, horizontal). A
relative ratio of protein species was determined by the ratio of fluorescent intensity at
identified spots in the gel. The image of the Cy3-labeled GFP eluate (green) and Cy5-
labeled MuRF1 eluate (Fig. 3 top left and bottom left, respectively) were overlaid to locate
differentially expressed spots (Fig. 3 top right). In the eluate comparison, we were interested
in spots that were ≥1.5-fold more red than green (yellow spots represent similar protein
amounts) indicating potential protein species that were more abundant in the MuRF1 eluate
sample. Differential spots in the other two gels that met both quality standards and were
changed in the expected direction were also identified as “picks” (for additional gel image
data, see Supplementary Fig. 1).
Picks that pass all three selection criteria and subsequent protein identification by MALDI-
TOF identify candidate MuRF1 substrates
We tabulated all of the individual spots that passed the selection criteria from each gel
comparison; for a list of all the spots “picked” in each comparison, see Supplementary Table
1. In total, there were nine spots that satisfied all three gel comparison criteria (highest
confidence, Supplementary Table 1), and an additional seven spots that satisfied criteria in
Gel 1 and Gel 2 (high confidence, Supplementary Table 1) for gain-of-function substrate
identification (Fig. 1). These 16 spots all fell within the intermediate to low pH range,
spanning a molecular weight range of 20–75 × 103 Daltons (Fig. 3 upper right, boxed
region). As a reference, we included a ratio image of this region to highlight the fold
enrichment of these samples in the MuRF1 TUBE elution relative to the GFP TUBE elution
as well as an annotated ratio image to highlight and label the 16 spots (Fig. 3, bottom right).
The 16 spots were picked from an independently run “pick” gel and submitted for protein
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identification using MALDI-TOF. Peptide sequencing identified a total 20 polypeptides
identified from the 16 spots (Table 1, Supplementary Table 2 and Supplementary data file).
Consistent with our hypothesis and validation of our proof-of-principal, three of the 20
proteins were previously identified in our yeast two-hybrid screen (9) or a published yeast
two-hybrid screen (30) and all but one of the proteins (Coq9) have been published as an
identified polyubiquitinated protein (30–33). Additionally, the functional classification of
the proteins identified included both structural (sarcomeric) protein components and
mitochondrial substrates, two known locations within the cardiomyocyte where MuRF1 is
known to function (30,34,35), suggesting this approach may, in fact, identify bona-fide
MuRF1 substrates.
Validation of Hspd1, Tpm1, and Atp5b as substrates of MuRF1
To determine if the candidate proteins identified in our 2D-DIGE method were substrates of
MuRF1, we took advantage of available antibodies and purified recombinant proteins to
validate selected candidates. First, we measured the pattern of Hspd1 (Fig. 3, spot #764)
modification in primary cardiomyocytes transduced with either Ad-GFP or Ad-MuRF1 via
SDS-PAGE/immunoblot analysis from independent experiments prepared with TUBE or
control agarose identically as described in the 2D-DIGE screen. As expected, in cells
overexpressing MuRF1, we detected several higher molecular weight proteins bound to the
TUBE beads that were reactive to the Hspd1 antibody (Fig. 4A), consistent with a MuRF1-
dependent increase in Hspd1 polyubiquitination. To determine if our primary cell system of
MuRF1 overexpression accurately reflected the action of increased MuRF1 activity in vivo,
we immunoprecipitated Hspd1 as well as another MuRF1 substrate candidate Tpm1 (Fig. 3,
spot #1339) from heart tissue isolated from either wild-type or MuRF1-transgenic mice (Fig.
4B). Consistent with the pattern observed in primary cardiomyocytes (Fig. 4A), after
successful immunoprecipitation of either candidate substrate protein, using immunoblot
analysis we observed increases in higher molecular weight proteins reactive to an antibody
that recognizes ubiquitin (Fig 4B) in MuRF1-trangenic hearts compared to wild-type hearts.
These data suggest that in vivo, both Hspd1 and Tpm1 are cardiac substrates of MuRF1;
furthermore, the translatability of using this ubiquitin ligase screen in our primary
cardiomyocyte culture model to identify in vivo cardiac substrates demonstrates the utility
of developing methods that are performed in a biologically relevant context. Finally, we
used a purified recombinant protein system to test if the candidate substrates Hspd1 and
Atp5b (Fig. 3, spot #941, #949, #972) could be polyubiquitinated by MuRF1 in a cell-free in
vitro system. Interestingly, in the absence of MuRF1 we observed E2-mediated
monoubiquitination (an emerging property of E2 enzymes; 36, 37) of both Hspd1 and
Atp5b,. As expected, we found both Hspd1 and Atp5b to be polyubiquitinated in the
presence of MuRF1, providing further validation that these proteins are direct substrates of
MuRF1. Through the use of multiple approaches we demonstrated that all three candidate
substrates identified by our 2D-DIGE method were validated as MuRF1 substrates.
Discussion
Ubiquitin ligases and their counter-regulatory de-ubiquitinating enzymes (DUBs) play
unique roles in protein ubiquitination and the UPS as the regulators of substrate specificity;
therefore, substrate identification is critical to the mechanistic understanding of the UPS as
well as our ability to modify protein ubiquitination in order to modulate disease. Despite
this, the available methods to identify ubiquitin ligase and DUB substrates do not provide
robust or unbiased means to identify physiological substrates, often relying upon non-
physiological in vitro approaches. Given the current limitations in ubiquitin substrate
screens, we developed a novel method for the identification of physiological ubiquitin
ligase/DUB substrates (Fig. 1). As a proof-of-principle for our method, we successfully
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utilized a transient gain-of-function model to screen for MuRF1 substrates in primary
cardiomyocytes (Fig. 2) and identified both previously identified MuRF1 substrates as well
as novel substrate proteins (Table 1). Not surprisingly, nearly all of the candidate substrates
were previously identified as polyubiquitinated proteins (30–33) ; additionally, the novel
candidate substrates were functionally classified in cellular locations where MuRF1 is
known to function including the sarcomere and mitochondria (30,34,35), reflective of the
physiological approach utilized by our method. Furthermore, we validated several novel
MuRF1 substrates both in vitro (Hspd1, Atp5b) and in vivo (Hspd1, Tpm1). In fact, the
increased in polyubiquitination of Hspd1 and Tpm1 in hearts of MuRF1 transgenic animals
not only validates the ability of our screen to identify novel substrates but also demonstrates
the unique translatability of this screening method performed in a biologically relevant
context to an independent in vivo model.
Our method circumvents major pitfalls of traditional substrate screens by: 1) using a
physiological setting that is relevant to the ubiquitin ligase/DUB or disease model; 2)
utilizing TUBE technology to isolate and protect the ubiquitome (25), independent of the
strength of the physical interaction between the ubiquitin ligase/DUB and substrate; and 3)
employing 2DDIGE with multiple subtractive comparisons to reduce the number of false
positives. For our proof-of-principle we used a biologically relevant primary cell culture
system; however, TUBE-based ubiquitome isolation can be used with a myriad of other
protein sources including stable cell culture models, isolated preparations of subcellular
compartments (for example, mitochondria, Rubel and Patterson – data not shown), and
animal tissues. The flexibility in starting material allows the study substrates of a ubiquitin
ligase, or the action of an opposing DUB (Fig. 1), under specific physiological or
pathophysiological conditions. We performed our screen using TUBE technology that has
an equal affinity to K63 and K48 ubiquitin linkages; however, there are other TUBE variants
that bind specific lysine linkages allowing the screen to be biased towards non-canonical
ubiquitinated substrates if desired. Moreover, we used semi-quantitative proteomics using
2D-DIGE, allowing high resolution separation and reduction of sample complexity prior to
mass spectrometric analysis, and enhancing accuracy of protein identification, while
avoiding issues of gel-to-gel variability associated with traditional 1D or 2D gel-based
proteomics (38). To minimize false positives, we coupled our 2D-DIGE strategy with a
multi-sample cross-comparison to achieve higher confidence in spot-picking prior to
MALDI-TOF peptide identification, the stringency of which could be increased or decreased
based on the user’s preference for confidence (Supplementary Table 1).
We realize that there are other modifications to this protocol that could be used to refine
substrate identification. Although we did not include proteasome inhibition to our protocol,
an approach that is often used in interaction-based methods, the inclusion of a proteasome
inhibitor such as MG132 for cell-based protein sources prior to protein extraction would
likely increase the pool of K48-linked polyubiquitinated proteins. In addition, there are other
protein identification methods that could be used in place of 2D-DIGE/MALDI-TOF as
there are limitations to a gel-based approach including difficulty detecting very hydrophobic
proteins, proteins with extreme molecular weights and pI values, as well as the potential
limited availability of 2D-DIGE facilities and personnel with the required expertise. With
minimal modification this method could be used with gel-free quantitative proteomics
strategies such Tandem Mass Tags (TMT) or Isobaric Tags for Relative and Absolute
Quantification (iTRAQ) to identify and quantitate proteins in each of the collected eluate
and supernatant samples (39). It should be noted that, even with the use of a gel-free based
approach, the same subtractive approach could be used to reduce false positives. With the
robust, flexible nature of the protocol described here, we are hopeful that this method will be
broadly applied to the study of both ubiquitin ligases and DUBs and through the
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identification of their substrates, aid in the understanding of these unique and important
regulatory proteins.
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Figure 1. Schematic model representing the ubiquitin ligase/deubiquitinating enzyme screening
platform
Protein is isolated from control and experimental animal tissue or cell culture samples where
the expression or activity of a ubiquitin ligase or deubiquitinating enzyme of interest is
manipulated to increase or decrease, dubbed a gain-of-function or loss-of-function
manipulation. Isolated protein is then quantitated and incubated overnight at 4 °C with
Tandem Ubiquitin Binding Entities (TUBE) or agarose control beads. Both the bound
(eluate) and unbound (supernatant) fractions are collected and subjected to 2D-DIGE. Three
different 2D-DIGE gels are run, each also including a pooled internal standard sample. Gel 1
compares the control sample ubiquitin enrichment to the experimental sample ubiquitin
enrichment, identifying proteins whose ubiquitination is dependent upon the ubiquitin ligase
Rubel et al. Page 13













of interest. The second and third gels allow comparisons of the TUBE-selected ubiquitomes
within the experimental condition (Gel 2) or control condition (Gel 3) by comparing the
ubiquitin-depleted supernatants from the sample incubated with TUBE to the ubiquitin-rich
sample incubated with agarose control beads. The comparison on Gel 2 identifies proteins
whose ubiquitination is potentially dependent upon the ubiquitin ligase of interest. The Gel 3
comparison reveals naturally occurring ubiquitinated proteins, as here, the ubiquitin ligase of
interest is unperturbed. Spots are identified as “picks” by DeCyder Analysis Software based
upon the determination of relative changes in intensity between the two samples and picks
are aligned across all three gel comparisons to select spots for subsequent MS/MS peptide
sequencing and protein identification.
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Figure 2. MuRF1 ectopic expression and TUBE-mediated ubiquitin enrichment
Fluorescent imaging and immunoblot verified MuRF1 ectopic expression and ubiquitin
enrichment prior to 2D-DIGE a Representative fluorescence micrographs of primary
cardiomyocytes after 24 h of transduction with adenovirus expressing green fluorescent
reporter protein alone (Ad-GFP) or in combination with Myc-tagged MuRF1 (Ad-MuRF1)
at MOI of 10. b Representative immunoblots (IB) of Myc, MuRF1, and GAPDH protein
levels in extracts isolated from primary cardiomyocytes transduced with Ad-GFP (−) or Ad-
MuRF1 (+) adenovirus for 24 h. The red arrow indicates endogenous MuRF1, with
ectopically-expressed myc-tagged MuRF1 migrating at a slightly higher molecular weight. c
Representative immunoblot of total ubiquitin from TUBE enrichment in extracts isolated
from primary cardiomyocytes transduced with Ad-GFP (G) or Ad-MuRF1 (M) for 24 h as
performed in the 2D-DIGE MuRF1 substrate screen. Lanes 1 and 2: input samples; lanes 3
and 4: unbound TUBE supernatant collected; lanes 5 and 6: ubiquitinated protein
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enrichment eluted from TUBE. From 3 independent experiments we observed an average of
30 ± 14.7% increase in total ubiquitinated protein with MuRF1 ectopic expression as
measured by densitometry.
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Figure 3. 2D-DIGE gel of the TUBE-isolated ubiquitome
2D-DIGE image analysis of ubiquitin-enriched samples eluted from TUBE identified spots
for mass spectrometry protein identification. Proteins eluted from TUBE incubated with
protein extract from Ad-GFP or Ad-MuRF1 transduced cardiomyocytes were labeled with
Cy3 and Cy5, respectively, and separated by molecular weight and isoelectric point (Cy3-
GFPeluate and Cy5-MuRF1eluate, top left and bottom left, respectively). Relative changes in
protein spots were calculated using the ratio of fluorescence intensity of each fluorescent
channel visualized by coloring and overlaying the Cy3-GFPeluate (green) and Cy5-
MuRF1eluate images (top right). The region containing the 16 spots selected for mass
spectrometry identification (top right, hashed white box) was magnified and used to generate
a ratio image (Cy5/Cy3) to highlight the fold-enrichement and identification of each picked
spot (bottom right).
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Figure 4. Validation of screen-identified proteins Hspd1, Tpm1, and Atp5b as substrates of
MuRF1
In vitro and in vivo data demonstrate that the screen-identified proteins Hspd1, Tpm1 and
Atp5b, are MuRF1 substrates. a Representative immunoblot (IB) of Hspd1 protein levels in
extracts isolated from primary cardiomyocytes transduced with Ad-GFP (G) or Ad-MuRF1
(M) adenovirus for 24 h. Lane 1 and 2: input samples (light exposure, see Supplementary
Fig. 2); lane 3 and 4: Ad-GFP samples eluted from either TUBE (Tu) or agarose control
beads (Ag); Lane 5 and 6: Ad-MuRF1 samples eluted from TUBE (Tu) or agarose control
beads (Ag). b Immunoprecipitations (IP) of Hspd1 and Tpm1 in extracts isolated from wild-
type (WT) or MuRF1 transgenic (TG) mouse hearts, subsequently immunoblotted (IB) for
Hspd1 or Tpm1 and ubiquitin (Ub). Lane 1 and 2: IgG control IP; lane 3 and 4: Hspd1 (top)
or Tpm1 (bottom) IP; Lane 5 and 6: 10% input of extract. Red arrows indicate ubiquitin-
reactive Hspd1 or Tpm1 species in MuRF1 Tg hearts (lane 4) that are not present or are of
lower relative abundance in wild-type hearts (lane 3). The black arrow indicates a non-
specific band also present in the IgG control IP. c In vitro ubiquitination assays for MuRF1
ubiquitination of Hspd1 and Atp5b performed in presence or absence of purified ubiquitin or
MuRF1 as indicated and detected by immunoblot analysis (IB) for Hspd1 (top) or Atp5b
(bottom).
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Table 1
Identities and characterization of MuRF1 substrates identified by MS/MS analysis of
selected 2D-DIGE spots
Symbols, descriptions and PANTHER protein classifications for each of the MuRF1 substrates identified by
mass spectroscopy analysis are listed. Also indicated are those proteins previously identified as MuRF1
substrates by yeast two-hybrid screening (Y2H (9,30) and Cam Patterson – data not shown) and those proteins
previously reported as MuRF1 substrates (or interacting proteins) in skeletal muscle.
Symbol Protein description Reportedsubstrate
Identified
by Y2H PANTHER Protein Class
ACTB Actin, cytoplasmic 1 actin and actin related protein
ACTC1 Actin, alpha cardiac muscle 1 skeletal(40) yes (9) actin and actin related protein
ATP5B ATP synthase subunit beta, mitochondrial yes (30) ATP synthase/ionchannel/hydrolase
COQ9 Ubiquinone biosynthesis protein COQ9,mitochondrial cofactor biosynthesis*
HNRNPF Heterogeneous nuclear ribonucleoprotein F ribosomal protein
HSPA5 78 kDa glucose-regulated protein Hsp70 family chaperone
HSPD1 60 kDa heat shock protein, mitochondrial chaperonin
LDHB L-lactate dehydrogenase B chain dehydrogenase
MDH1 Malate dehydrogenase, cytoplasmic dehydrogenase
MURF1 E3 ubiquitin-protein ligase TRIM63 (MuRF1) auto Ub ubiquitin-protein ligase
MYL2 Myosin regulatory light chain 2,ventricular/cardiac muscle isoform
skeletal
(41) yes (9) cytoskeletal protein
MYL3 Myosin light chain 3 skeletal(41) yes (9)
actin family cytoskeletal
protein/calmodulin
PDIA6 Protein disulfide-isomerase A6 isomerase




TOLLIP Toll-interacting protein adapter protein*
TPM1 Isoform 1 of Tropomyosin alpha-1 chain actin binding motor protein
TUBA1A Tubulin alpha-1A chain tubulin
TUBB2C Tubulin beta-2C chain tubulin
TUBB5 Isoform 1 of Tubulin beta-5 chain tubulin
VIM Vimentin structural protein/intermediatefilament
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